Skip to main content
Tomer Mark, MD, Oncology, Aurora, CO

TomerMarkMD

Oncology Aurora, CO

Associate Professor, University of Colorado, Anschutz Medical Campus

Dr. Mark is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Mark's full profile

Already have an account?

  • Office

    12605 E 16th Ave
    # Univ
    Aurora, CO 80045
    Phone+1 720-848-0000

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2005 - 2008
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2002 - 2005
  • Stony Brook University Health Sciences Center School of Medicine
    Stony Brook University Health Sciences Center School of MedicineClass of 2002
  • Yale University
    Yale UniversityB.S., Molecular Biophysics and Biochemistry, Cum Laude, 1998

Certifications & Licensure

  • CO State Medical License
    CO State Medical License 2016 - 2025
  • NY State Medical License
    NY State Medical License 2005 - 2022
  • WY State Medical License
    WY State Medical License 2021 - 2022

Awards, Honors, & Recognition

  • Named as Super Doctors Rising Star for New York 2015
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
  • Clinical Research Training Institute Award American Society of Hematology, 2008
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Autologous/Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Tandem Autologous Transplantation for Multiple Myeloma - Comparison of Long Term Post Relapse Sur...  
    Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, ..., Biol Blood Marrow Transplant, 1/24/2017
  • Cellular Proliferation by Multiplex Immunohistochemistry Identifies High Risk Multiple Myeloma in Newly Diagnosed, Treatment Naïve Patients  
    Ely S, Forsberg P, Ousansafi I, Rossi A, Modin A, Pearse R, Pekle K, Perry A, Coleman M, Jayabalan D, Di Liberto M, Chen-Kiang S, Niesvizky R, Mark TM, Clin Lymphoma Myeloma Leuk, 1/20/2017
  • Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices  
    Singh AD, Parmar S, Patel K, Shah S, Shore T, Gergis U, Mayer S, Phillips A, Hsu JM, Niesvizky R, Mark TM, Pearse R, Rossi A, van Besien K, Biol Blood Marrow Transplant, 1/20/2017
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples
    Tomer M Mark, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Efficacy and Safety of Daratumumab, Bortezomib and Dexamethasone (Dvd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Upda...
    Weisel K, Lentzsch S, Mateos MV, Hungria V, Munder M, Nooka A, Mark T, Quach H, Scott EC, Lee JJ, Sonneveld P, Casneuf T, Chiu C, Qin X, Amin H, Thiyagarajah P, Schect..., Haematologica; European Hematology Association Meeting, 1/1/2017
  • Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Mye...
    Chari A, Mark TM, Krishnan A, Stockerl-Goldstein K, Usmani SZ, Londhe A, Etheredge D, Parros H, Fleming S, Liu BL, Freeman S, Ukropec J, Lin T, Nooka AK, American Society of Hematology, 1/1/2016
  • Join now to see all

Lectures

  • Best of Myeloma at ASH 2016. 
    University of Colorado - 1/27/2017
  • In the relapsed patient, what would be the ideal treatment? 
    New York, NY - 1/26/2017
  • New Drugs in Multiple Myeloma 
    University of Colorado, Anschutz Medical Campus - 1/9/2017
  • Join now to see all

Press Mentions

  • Oral Triplet Deemed Effective in relapsed/refractory Myeloma
    Oral Triplet Deemed Effective in relapsed/refractory MyelomaMarch 13th, 2019